Celldex Therapeutics, Inc. (NASDAQ: CLDX) Q1 2025 Earnings Call | 06/13/2025

About this video

Celldex Therapeutics, Inc. reported Q1 2025 results on June 13, 2025, highlighting both significant clinical progress and ongoing financial investment in its late-stage pipeline. Total revenue for the quarter was $0.7 million, up from $0.2 million a year ago, primarily reflecting increased services under R&D agreements. The company posted a net loss of $53.8 million, or ($0.81) per share, compared to a net loss of $32.8 million, or ($0.56) per share, in Q1 2024. The higher loss was mainly driven by increased R&D expenses, which rose to $52.6 million as Celldex advanced its lead candidate barzolvolimab through multiple late-stage trials. Celldex maintains a robust cash position, ending the quarter with $673.3 million in cash, cash equivalents, and marketable securities. This strong balance sheet is expected to fund operations through at least 2027, supporting the company’s ambitious clinical agenda. The quarter was marked by promising clinical data for barzolvolimab in chronic spontaneous urticaria (CSU). At the EAACI Congress 2025, Celldex presented 76-week data from its Phase II study, showing unprecedented response rates—including some patients maintaining complete responses seven months after their final treatment. These results suggest the therapy may “reset” the immune system, a finding that has drawn strong analyst support and multiple “Buy” or “Overweight” ratings with price targets ranging from $46 to $67, far above the current share price. Celldex is also advancing Phase 3 studies in CSU and chronic inducible urticaria (CIndU), with additional analyses underway for angioedema and other indications. The company’s pipeline includes ongoing Phase 2 and Phase 1 studies in eosinophilic esophagitis, prurigo nodularis, atopic dermatitis, and its first bispecific antibody for inflammatory diseases. Outlook: Celldex expects its cash reserves to support operations and clinical development through 2027. Additional late-stage clinical data readouts are anticipated in 2025, with ongoing enrollment in multiple Phase 2 and Phase 3 trials. Analysts remain bullish on Celldex’s potential, citing barzolvolimab’s best-in-class efficacy and the company’s strong financial position as key strengths. #Celldex #CLDX #EarningsCall #Q12025 #Barzolvolimab #CSU #ClinicalTrials #Biotech #Investing #InsideTicker